Company Overview

Cellectis S.A. is a clinical-stage biotechnology company specializing in gene‑edited cell therapies, primarily for oncology indications. The company operates within the biotechnology and biopharmaceutical industries, with a focus on developing allogeneic (off‑the‑shelf) CAR T‑cell therapies enabled by proprietary gene‑editing technologies. Its core revenue drivers are research collaborations, licensing arrangements, and milestone or service revenues, as the company does not currently generate commercial product sales.

Founded in 1999, Cellectis pioneered the application of engineered nucleases for precise genome editing and later transitioned its strategic focus toward allogeneic CAR T‑cell immunotherapies. The company is differentiated by its ownership of the TALEN® gene‑editing technology, which enables multiplex gene editing to create standardized cell therapy products designed for broader patient access compared with autologous approaches. Over time, Cellectis evolved from a broad genome‑editing platform company into a vertically integrated cell therapy developer with in‑house manufacturing capabilities.

Business Operations

Cellectis conducts operations through integrated research, development, and manufacturing activities centered on gene‑edited allogeneic CAR T‑cell candidates. Its primary business lines include oncology drug discovery, preclinical research, clinical development, and clinical‑grade cell manufacturing. The company’s therapeutic pipeline targets hematologic malignancies and selected solid tumors, with programs advancing through early‑stage and mid‑stage clinical trials.

Operations are supported by proprietary technologies, including TALEN® gene‑editing, electroporation systems, and internal cell manufacturing platforms. Cellectis controls and operates manufacturing facilities designed for clinical‑stage production and maintains collaborative relationships with pharmaceutical partners. Notable subsidiaries include Cellectis, Inc., which supports U.S. clinical and operational activities, and Calyxt, Inc. (historically), though Calyxt has since become independent and is no longer consolidated.

Strategic Position & Investments

The company’s strategic direction emphasizes advancing a wholly owned pipeline of allogeneic CAR T‑cell therapies while selectively partnering to offset development risk and fund operations. Growth initiatives focus on expanding clinical programs, optimizing next‑generation CAR constructs, and improving manufacturing scalability and durability of therapeutic response. Cellectis has historically entered into strategic collaborations with large pharmaceutical companies to co‑develop or license gene‑edited cell therapy assets.

Cellectis has made targeted investments in manufacturing infrastructure and platform enhancements rather than large‑scale acquisitions. Its strategic assets include intellectual property surrounding TALEN® technology and cell therapy manufacturing know‑how. The company remains positioned at the intersection of gene editing and immuno‑oncology, two rapidly evolving biotechnology sectors, with continued emphasis on translational research and clinical validation.

Geographic Footprint

Cellectis is headquartered in France, with principal operations in Paris, and maintains a significant operational presence in the United States. Its U.S. activities, including clinical development and regulatory engagement, are primarily conducted through facilities in New York and other biotechnology hubs.

The company’s market and clinical footprint spans Europe and North America, where most of its trials, partnerships, and regulatory interactions occur. While Cellectis does not maintain broad commercial operations internationally, its technologies and clinical programs have global relevance, and its intellectual property portfolio supports potential future expansion into additional regions.

Leadership & Governance

Cellectis is led by an executive team with expertise in biotechnology, gene editing, and pharmaceutical development. Governance is overseen by a board of directors with experience in life sciences, finance, and corporate strategy, supporting a leadership philosophy centered on scientific rigor, disciplined capital allocation, and long‑term platform value creation.

Key executives include:

• André Choulika – Chief Executive Officer
• Philippe Lauger – Chief Financial Officer
• Dr. Marc Le Bozec – Chief Scientific Officer
• Dr. Raymund J. Ratan – Executive Vice President, Clinical Development
• David Baron – Chief Legal Officer and Corporate Secretary